[ad_1]
“This fifth agreement is another reference point “In our efforts to provide all citizens with a safe and effective way to address the pandemic,” he added.
Pfizer and BioNTech have announced that they will ship request today in US Food and Drug Administration (FDA) for emergency use (USA) of the candidate vaccine MRNA, BNT162b2 against SARS-CoV-2, which may allow use of the vaccine to the high-risk population in the U.S. from mid-to-middling end of December 2020.
The presentation is based on 95% vaccine efficacy rate, demonstrated in phase 3 of the clinical study of companies in participants without a prior SARS-CoV-2 infection (first primary target) and also in participants with and without a previous SARS-CoV-2 infection (second primary target).
“Our job is provide a safe and effective vaccineIt has never been more urgent, as we continue to see a worrying increase in the number of COVID-19 cases around the world. Shipping to the US represents a critical milestone in our journey to deliver the COVID-19 vaccine to the world and now we have a more complete picture of both the efficacy and the safety profile of the vaccine “giving us confidence in their abilities,” said Dr. Albert Mockery, President and CEO of Pfizer.
